Literature DB >> 22811079

Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia.

Kathryn S Sutton1, Evan B Shereck, Eneida R Nemecek, Peter Kurre.   

Abstract

BACKGROUND: To investigate the immune status among pediatric patients with aplastic anemia (AA) and explore PNH-status, T-regulatory and NK-cell frequency as potential markers of clinical response.
METHODS: Data were retrospectively analyzed from twenty-six patients diagnosed with AA. PNH populations, T- and NK-subsets were determined via flow cytometry.
RESULTS: At diagnosis, 9/23 patients with severe AA (SAA) versus 1/3 with moderate AA (MAA) were PNH(pos) . Among PNH(pos) patients treated with ATG based immunosuppression, 2/6 had a complete response (CR), while 4/6 had a partial response (PR), similarly 2/6 PNH(neg) patients had a CR and 4/6 had a PR. Lymphocyte subset immunophenotyping revealed that T-regulatory cells represented 7.2% of total lymphocytes at diagnosis. Their frequency varied with disease severity (5.5% for SAA and 14.1% for MAA) and response (8.9% for CR and 1.5% for PR), generally increasing following therapy with IST (14.6%). The NK cell frequency was not substantially different based on disease severity or response.
CONCLUSIONS: Neither PNH cell populations, nor NK cell frequency corresponded with disease severity or response. T-regulatory cell frequency, although not statistically significant given the small sample size, corresponded with both severity and response, indicating potential utility as a prognostic tool.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22811079     DOI: 10.1002/pbc.24247

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.

Authors:  Nathalie Bleyzac; Michaël Philippe; Amandine Bertrand; Yves Bertrand
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

2.  Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.

Authors:  Michaël Philippe; Emilie Hénin; Yves Bertrand; Dominique Plantaz; Sylvain Goutelle; Nathalie Bleyzac
Journal:  AAPS J       Date:  2015-05-15       Impact factor: 4.009

3.  Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia.

Authors:  Jin Hayakawa; Junya Kanda; Yu Akahoshi; Naonori Harada; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Shun-Ichi Kimura; Misato Kikuchi; Rie Yamazaki; Shinichi Kako; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2017-01-11       Impact factor: 2.490

Review 4.  The complex pathophysiology of acquired aplastic anaemia.

Authors:  Y Zeng; E Katsanis
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

Review 5.  Acquired aplastic anemia in children.

Authors:  Helge D Hartung; Timothy S Olson; Monica Bessler
Journal:  Pediatr Clin North Am       Date:  2013-10-16       Impact factor: 3.278

Review 6.  Aplastic anemia during pregnancy: a review of obstetric and anesthetic considerations.

Authors:  Efrain Riveros-Perez; Amy C Hermesch; Linda A Barbour; Joy L Hawkins
Journal:  Int J Womens Health       Date:  2018-02-28

7.  Paroxysmal nocturnal hemoglobinuria clones in children with acquired aplastic anemia: a multicentre study.

Authors:  Fabio Timeus; Nicoletta Crescenzio; Daniela Longoni; Alessandra Doria; Luiselda Foglia; Sara Pagliano; Stefano Vallero; Valentina Decimi; Johanna Svahn; Giuseppe Palumbo; Antonio Ruggiero; Baldassarre Martire; Marta Pillon; Nicoletta Marra; Carlo Dufour; Ugo Ramenghi; Paola Saracco
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.